Ajax Therapeutics, Inc.

About Ajax Therapeutics, Inc.

Ajax Therapeutics is a biotechnology company focused on developing targeted therapies for hematologic cancers, specifically myeloproliferative neoplasms (MPNs). By leveraging state-of-the-art computational chemistry and structural biology, Ajax aims to create best-in-class therapies with greater precision to address significant unmet medical needs in this area.

Products & Services

AJ1-11095:A first-in-class Type II JAK2 inhibitor for the treatment of myelofibrosis, currently in Phase 1 clinical trials.

AJ1-10502:A next-generation Type II JAK2 inhibitor with preclinical data showing superior selectivity and efficacy in models of myeloproliferative neoplasms.

Specialties

Hematologic Cancers Myeloproliferative Neoplasms (MPNs) JAK2 Inhibitors Computational Chemistry Structural Biology Targeted Therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 95000000 MR: - FA: $95 million FAN: 95000000	D: 2024-05-13 FD: 2024-05-13	9 investors

Series C Latest

2024-05-13

$95.0M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Martin Vogelbaum

CEO

D

David P. Steensma

Chief Medical Officer

C

Craig E. Masse

Senior Vice President, Discovery Research

D

David Waller

Senior Vice President and Head of CMC

M

Maria Kleppe

Executive Director, Discovery Biology

C

Christine Richardson

Senior Director, Program Management

View 16 more team members with Pro

Unlock Full Team Directory

Recent News